Novo Nordisk A/S: Tresiba® (insulin degludec) approved in Japan

Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Tresiba® (insulin degludec) for the treatment of diabetes. Media: Investors: Mike Rulis Kasper Roseeuw Poulsen Tel: (+45) 3079 3573 Tel: (+45) 4442 4303 [email protected] [email protected] Frank Daniel Mersebach Tel: (+45) 4442 0604 [email protected] Lars Borup Jacobsen Tel: (+45) 3075 3479 [email protected] In North America: Ken Inchausti Jannick Lindegaard Tel: (+1) 609 514 8316 Tel: (+1) 609 786 4575 [email protected] [email protected] Company Announcement No 59 / 2012

The release as fetched from its publisher. novonordisk.com ↗